BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 32596740)

  • 1. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
    Romanelli F; De Robertis A; Carone G; Dalfino L; Stufano M; Del Prete R; Mosca A
    New Microbiol; 2020 Jul; 43(3):136-138. PubMed ID: 32596740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing
    Huang Y; Sokolowski K; Rana A; Singh N; Wang J; Chen K; Lang Y; Zhou J; Kadiyala N; Krapp F; Ozer EA; Hauser AR; Li J; Bulitta JB; Bulman ZP
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0069221. PubMed ID: 34152820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
    Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
    Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
    Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
    Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of a Stable and Transferable
    Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
    Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Expression and Amplification of
    Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
    Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
    Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
    J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
    Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
    J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
    Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
    Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.
    Jousset AB; Oueslati S; Emeraud C; Bonnin RA; Dortet L; Iorga BI; Naas T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116021. PubMed ID: 34606331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.